Tests bleximenib in people with acute leukemia
Tests a new drug, bleximenib, for safety and dosing in acute leukemia.
Key facts
- Who runs it
- Janssen Research & Development, LLC
- Where
- Seoul, South KoreaSee the 3 sitesAlso in 12 other countries, 97 sites
- Registry title
- A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 420 people, planned
- Started
- 19 May 2021
- Expected to end
- 22 Sept 2030
- Type of study
- Interventional
- Treatments tested
- Bleximenib
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with acute leukemia that came back or did not respond to treatment, and that has certain gene changes (KMT2A, NPM1, NUP98 or NUP214).
- Age
- Phase 1: 2 years to under 18 years for the children's group, 18 years and above for all other groups. Phase 2: older than 18 years.
- Sex
- Men and women can join.
- Disease stage
- Acute leukemia that came back (relapsed) or did not respond to treatment (refractory), when other available treatments are used up or not possible. Phase 2: acute myeloid leukemia (AML) that came back or did not respond.
- Earlier treatment
- Cannot have had cancer immunotherapy within 4 weeks, blinatumomab within 2 weeks, or other cancer therapies within 4 weeks (or 5 half-lives of the drug, whichever is shorter), before joining. Other limits apply after stem cell transplant.
- Biomarker or test result
- Phase 1: leukemia with KMT2A, NPM1, NUP98 or NUP214 changes. Phase 2: AML with a KMT2A rearrangement or an NPM1 mutation only.
Main reasons for not taking part
- Acute promyelocytic leukemia, Down syndrome associated leukemia or juvenile myelomonocytic leukemia
- Active central nervous system (CNS) disease
- Prior solid organ transplant
- Certain heart rhythm test results (QTcF 450 msec or more in males, 470 msec or more in females) or a family history of Long QT syndrome
- Stem cell transplant within 3 months, graft versus host disease, or need for immunosuppressant therapy
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Phase 1:
- Age 2 years to less than (<) 18 years of age (pediatric cohort only), all other cohorts 18 years and above
- Relapsed or refractory (R/R) acute leukemia and has exhausted, or is ineligible for, available therapeutic options
- Acute leukemia harboring histone-lysine N-methyltransferase 2A (KMT2A), nucleophosmin 1 gene (NPM1) or nucleoporin 98 gene or nucleoporin 214 gene (NUP98 or NUP214) alterations; Phase: 2
- Participants greater than 18 years are eligible
- Must have had an initial diagnosis of acute myeloid leukemia (AML) per the WHO 2022 classification criteria and have relapsed/refractory disease
- AML harboring KMT2A-r (gene rearrangement/translocation) or NPM1 mutations only; For Both Phase 1 and 2:
- Pretreatment clinical laboratory values meeting the following criteria: (a) Hematology: white blood cell (WBC) count <= 20*10\^9/liter (L) and (b) renal function; For adult participants, estimated or measured glomerular filtration rate >= 30 milliliter per minute (mL/min) per four variable MDRD equation. For pediatric participants an estimated or measured glomerular filtration rate >=40 mL/min per the CKiD (Chronic Kidney Disease in Children) Schwartz formula
- Eastern Cooperative Oncology Group (ECOG) performance status grade of 0, 1 or 2. Pediatric participants only: Performance status >=70 by Lansky scale (for participants < 16 years of age) or >=70 Karnofsky scale (for participants >=16 years of age)
- A female of childbearing potential must have a negative highly sensitive serum beta-human chorionic gonadotropin at screening and within 48 hours prior to the first dose of study treatment
- Participant must agree to all protocol required contraception requirements and avoid sperm or egg donations or freezing for future reproductive use while on study and for 90 days (males) or 6 months (females) after the last dose of study treatment
Who cannot take part
- Prior solid organ transplantation
- Acute promyelocytic leukemia, diagnosis of Down syndrome associated leukemia or juvenile myelomonocytic leukemia according to World Health Organization (WHO) 2016 criteria
- Active central nervous system (CNS) disease
- Prior cancer immunotherapy within 4 weeks prior to enrollment or blinatumomab within 2 weeks prior to enrollment. Additional prior cancer therapies must not be given within 4 weeks prior to enrollment or 5 half-lives of the agent (whichever is shorter)
- QTc according to Fridericia's formula (QTcF) for males >= 450 millisecond (msec) or for females >= 470 msec. Participants with a family history of Long QT syndrome are excluded
- Exclusion criteria related to stem cell transplant: a. Received prior treatment with allogenic bone marrow or stem cell transplant <=3 months before the first dose of study treatment ; b. Has evidence of graft versus host disease; c. Received donor lymphocyte infusion <=1 month before the first dose of study treatment; d. Requires immunosuppressant therapy (exception: daily doses <=10 milligrams (mg) prednisone or equivalent are allowed for adrenal replacement)
Where in South Korea
Also in 12 other countries, 97 sites
- Asan Medical CenterSeoul, South KoreaTaking people
- Samsung Medical CenterSeoul, South KoreaTaking people
- Seoul National University HospitalSeoul, South KoreaTaking people
About the trial
What the trial wants to find out
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of bleximenib in phase 1 Part 1 (Dose Escalation) and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Phase 2 part of the study is to evaluate the efficacy of bleximenib at the RP2D.
The group in the trial
- BleximenibTreatment being tested
Participants in Phase 1 Part 1 (dose escalation) will receive bleximenib orally. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Doses (RP2Ds) have been identified. Participants in Phase 1 Part 2 (dose expansion) will receive bleximenib orally at the RP2D(s) determined in Part 1. In Phase 2 participants will receive bleximenib at the RP2D to evaluate anti-leukemia activity and demonstrate acceptable safety at the RP2D(s).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
- Plain-language title
- Tests bleximenib in people with acute leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 4 November 2026